- Home
- PAVM vs PRPO Comparison
PAVM vs PRPO Comparison
Compare PAVM & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | PRPO |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | 41 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.8M | 40.1M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | PAVM | PRPO |
|---|---|---|
| Price | $4.93 | $23.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $65.00 | N/A |
| AVG Volume (30 Days) | ★ 19.7K | 18.5K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | $603.94 | N/A |
| Revenue Next Year | $33.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $0.21 | $10.60 |
| 52 Week High | $28.44 | $33.63 |
Technical Indicators
Market Signals| Indicator | PAVM | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 40.36 | 43.02 |
| Support Level | $4.50 | $21.71 |
| Resistance Level | $6.56 | $25.27 |
| Average True Range (ATR) | 0.61 | 1.22 |
| MACD | 0.05 | 0.20 |
| Stochastic Oscillator | 36.98 | 48.61 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
About PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.